Q-omics provides the consensus-scored ADAMTS15 profile across patient tissues and cancer cell-line models. ADAMTS15 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ADAMTS15 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ADAMTS15 RNA expression shows 16,628 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight BLCA, HNSC, and BRCA as cancer lineages where ADAMTS15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADAMTS15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADAMTS15 survival associations across molecular data types. ADAMTS15 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADAMTS15 RNA expression–survival associations across cancer types. High ADAMTS15 expression shows unfavorable associations in BLCA, HNSC, STAD, UVM and CESC, but favorable associations in ESCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for ADAMTS15 RNA expression.
This table summarizes ADAMTS15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ADAMTS15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADAMTS15 shows lower tumor expression in KICH, KIRC, LUAD, BLCA and LUSC and higher tumor expression in HNSC. The HNSC box plot shows higher ADAMTS15 RNA expression in tumor versus normal tissue (log2 FC = +2.101, t-test p < 0.001).
This table shows molecular features associated with ADAMTS15 in patient tissues and cancer cell lines. In patient samples, ADAMTS15 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, ADAMTS15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BONE.
